2型糖尿病患者新型长效胰岛素处方:患病率与临床实践差异的回顾性队列研究
该回顾性队列研究基于荷兰全科医学数据库,纳入2018年首次处方中效或长效胰岛素的≥40岁使用其他降糖药的2型糖尿病患者,分析新型长效胰岛素(甘精胰岛素300 U/mL和德谷胰岛素)的处方实践差异及相关因素。结果显示各全科诊所处方新型胰岛素的中位比例为21.2%(IQR 12.5-36.4%),诊所间差异大且仅部分由患者和诊所特征解释。
要点
- 各全科诊所处方新型长效胰岛素的中位比例为21.2%(IQR 12.5-36.4%)。
- 女性、高龄、使用二甲双胍或磺脲类药物与新型胰岛素处方几率降低相关。
- 使用其他新型降糖药和配药诊所与新型胰岛素处方几率升高相关。
核心结论
- 全科诊所间新型长效胰岛素处方差异大,仅部分由患者和诊所相关差异解释,提示有较大改善空间。
研究设计与样本
- 荷兰全科医学数据库(Nivel Primary Care Database)的回顾性队列研究,纳入282家全科诊所的7757例≥40岁使用其他降糖药的2型糖尿病患者,识别2018年首次中效或长效胰岛素处方。
主要发现
- 各诊所处方新型胰岛素的中位比例为21.2%(IQR 12.5-36.4%)。
- 多水平模型显示,女性(OR 0.77,95%CI 0.69-0.87)、年龄≥86岁较40-55岁(OR 0.22,95%CI 0.15-0.34)、二甲双胍处方(OR 0.66,95%CI 0.53-0.82)、磺脲类处方(OR 0.58,95%CI 0.51-0.66)与新型胰岛素处方几率降低相关。
- 其他新型2型糖尿病药物处方(OR 3.10,95%CI 2.63-3.66)和配药诊所(OR 1.78,95%CI 1.03-3.10)与新型胰岛素处方几率升高相关。
- 多水平建模后,组内相关系数(ICC)从20%降至19%。
临床怎么用
- 全科医生应关注新型长效胰岛素处方的实践差异,结合患者特征(如性别、年龄、合并用药)审慎选择,减少不必要的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about prescription patterns of expensive non-recommended newer long-acting insulins (glargine 300 U/mL and degludec) for patients with type 2 diabetes mellitus (T2DM). AIM: To identify practice variation in, and practice- and patient-related characteristics associated with, the prescription of newer long-acting insulins to patients with T2DM in primary care. DESIGN AND SETTING: A retrospective cohort study in Dutch general practices (Nivel Primary Care Database). METHOD: A first prescription for intermediate or long-acting insulins in 2018 was identified in patients aged ≥40 years using other T2DM drugs. Per practice, the median percentage and interquartile range (IQR) of patients with newer insulin prescriptions were calculated. Multilevel logistic regression models were constructed to calculate intraclass correlation coefficients (ICCs) and quantify the association of patient and practice characteristics with prescriptions for newer insulins (odds ratios [ORs] and 95% confidence intervals [CIs]). RESULTS: In total, 7757 patients with prescriptions for intermediate or long-acting insulins from 282 general practices were identified. A median percentage of 21.2% (IQR 12.5-36.4%) of all patients prescribed intermediate or long-acting insulins per practice received a prescription for newer insulins. After multilevel modelling, the ICC decreased from 20% to 19%. Female sex (OR 0.77, 95% CI = 0.69 to 0.87), age ≥86 years compared with 40-55 years (OR 0.22, 95% CI = 0.15 to 0.34), prescriptions for metformin (OR 0.66, 95% CI = 0.53 to 0.82), sulfonylurea (OR 0.58, 95% CI = 0.51 to 0.66), or other newer T2DM drugs (OR 3.10, 95% CI = 2.63 to 3.66), and dispensing practices (OR 1.78, 95% CI = 1.03 to 3.10) were associated with the prescription of newer insulins. CONCLUSION: The inter-practice variation in the prescription of newer insulins is large and could only be partially explained by patient- and practice-related differences. This indicates substantial opportunities for improvement.
引用
- Dankers M, Hek K, Nelissen-Vrancken M, et al. Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study. Br J Gen Pract. 2022. PMID: 35606162. doi:10.3399/BJGP.2021.0581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。